Stocks Hitting 52-Week Highs

shares reached a new 52-week high of $10.29 after the company reported Breakthrough Therapy designation for Azedra in pheochromocytoma and paraganglioma.

shares climbed 13.55 percent to touch a new 52-week high of $202.32 after the company reported upbeat Q2 results.

shares reached a new 52-week high of $82.06 after the company reported better-than-expected Q2 earnings and lifted its earnings forecast.

shares touched a new 52-week high of $19.94 on stronger-than-expected Q2 earnings.